In vitro evaluation of folate-modified PLGA nanoparticles containing paclitaxel for ovarian cancer therapy

Autor(es):Mostrar menos -

Luiz, Marcela Tavares ^[1] ; Abriata, Juliana Palma ^[1] ; Raspantini, Giovanni Loureiro ^[1] ; Tofani, Larissa Bueno ^[1] ; Fumagalli, Fernando ^[1] ; Gil de Melo, Shaiani Maria ^[1] ; Emery, Flavio da Silva ^[1] ; Swiech, Kamilla ^[1] ; Marcato, Priscyla Daniely ^[1] ; Lee, Robert ^[2] ; Marchetti, Juliana Maldonado ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ave Cafe S-N, BR-14040903 Ribeirao Preto, SP - Brazil

^[2] Ohio State Univ, Div Pharmaceut & Pharmaceut Chem, Columbus, OH 43210 - USA

• Tipo de documento: Artigo Científico
• Fonte: Materials Science & Engineering C-Materials for Biological Applications; v. 105, DEC 2019.
• Citações Web of Science: 0

Resumo

Ovarian cancer is the most lethal gynecological cancer of female reproductive system. In order to improve the survival rate, some modifications on nanoparticles surfaces have been investigated to promote active targeting of drugs into tumor microenvironment. The aim of this study was the development and characterization of folate-modified (PN-PCX-FA) and unmodified PLGA nanoparticles (PN-PCX) containing paclitaxel for ovarian cancer treatment. Nanocarriers were produced using nanoprecipitation technique and characterized by mean particle diameter (MPD), polydispersity index (PDI), zeta potential (ZP), encapsulation efficiency (EE), DSC, FTIR, in vitro cytotoxicity and cellular uptake. PN-PCX and PN-PCX-FA showed MPD < 150 nm and PDI < 0.2 with high EE (about 90%). Cytotoxicity assays in SKOV-3 cells demonstrated the ability of both formulations to cause cellular damage. PCX encapsulated in PN-PCX-FA at 1 nM showed higher cytotoxicity than PN-PCX. Folate-modified nanoparticles showed a 3.6-fold higher cellular uptake than unmodified nanoparticles. PN-PCX-FA is a promising system to improve safety and efficacy of ovarian cancer treatment. Further in vivo studies are necessary to prove PN-PCX-FA potential. (AU)

• Processo FAPESP: 16/03170-2 - Desenvolvimento e caracterização de nanopartículas de PLGA funcionalizadas com folato contendo paclitaxel para a otimização da terapia do câncer de ovário
• Beneficiário: Marcela Tavares Luiz
• Modalidade de apoio: Bolsas no Brasil - Mestrado